Wells Fargo & Company Avalo Therapeutics, Inc. Transaction History

Wells Fargo & Company

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$3.0 - $10.45 $39,939 - $139,120	-13,313 Reduced 88.58%	1,716 $0
Q1 2022 May 16, 2022	SELL	$7.57 - $21.72 $202,838 - $581,987	-26,795 Reduced 64.07%	15,029 $11,000
Q4 2021 Feb 14, 2022	BUY	$19.68 - $28.68 $801,960 - $1.17 Million	40,750 Added 3794.23%	41,824 $72,000
Q3 2021 Nov 15, 2021	BUY	$26.16 - $40.68 $28,095 - $43,690	1,074 New	1,074 $2,000

34.6K

Ticker AVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 9,414,100
Market Cap $91.6M
Description
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the tr...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.